NCT06422377View on ClinicalTrials.gov

A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine

PHASE3TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

April 25, 2024

Primary Completion Date

August 14, 2024

Study Completion Date

August 14, 2024

Conditions
Dravet Syndrome (DS)Lennox-Gastaut Syndrome (LGS)
Interventions
DRUG

Soticlestat

Soticlestat tablets or mini-tablets

Trial Locations (1)

4293

Epilepsihospitalet Filadelfia, Dianalund

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY